Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study
Autore:
Phillips, KA; Albertini, RS; Siniscalchi, JM; Khan, A; Robinson, M;
Indirizzi:
Butler Hosp, Providence, RI 02906 USA Butler Hosp Providence RI USA 02906Butler Hosp, Providence, RI 02906 USA Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02912 USABrown Univ Providence RI USA 02912 Human Behav, Providence, RI 02912 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 9, volume: 62, anno: 2001,
pagine: 721 - 727
SICI:
0160-6689(200109)62:9<721:EOPFBD>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; STRUCTURED CLINICAL INTERVIEW; MAJOR DEPRESSIVE DISORDER; IMAGINED UGLINESS; FOLLOW-UP; RELIABILITY; VALIDITY; AUGMENTATION; FLUVOXAMINE; SCALE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Phillips, KA Butler Hosp, 345 Blackstone Blvd, Providence, RI 02906 USA Butler Hosp 345 Blackstone Blvd Providence RI USA 02906 6 USA
Citazione:
K.A. Phillips et al., "Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study", J CLIN PSY, 62(9), 2001, pp. 721-727

Abstract

Background: Research on the pharmacotherapy of body dysmorphic disorder (BDD) is limited. No placebo-controlled, continuation, maintenance, or discontinuation studies have been published. Only one augmentation study has beenpublished. Method: In this chart-review study of 90 patients with DSM-IV BDD treated for up to 8 years by the first 2 authors (K.A.P., R.S.A.) in their clinicalpractice, response to a variety of medications, including augmentation strategies, was assessed. The relapse rate with medication discontinuation wasalso determined. Results: All subjects received a serotonin reuptake inhibitor (SRI), with 63.2% (55/87) of adequate SRI trials resulting in improvement in BDD symptoms; similar response rates were obtained for each type of SRI. Discontinuation of an effective SRI resulted in relapse in 83.8% (31/37) of cases. Response rates to selective SRI augmentation were clomipramine, 44.4% (4/9) of trials; buspirone, 33.3% (12/36) of trials; lithium, 20.0% (1/5); methylphenidate, 16.7% (1/6); and antipsychotics, 15.4% (2/13) of trials. Conclusion: These findings from a clinical setting suggest that a majorityof BDD patients improve with an SRI and that all SRIs appear effective. Certain SRI augmentation strategies may be beneficial. The high relapse rate with SRI discontinuation suggests that long-term treatment is often necessary. These preliminary findings require confirmation in placebo-controlled efficacy studies and effectiveness studies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 13:21:17